Literature DB >> 15960772

Mental health policy and psychotropic drugs.

Richard G Frank1, Rena M Conti, Howard H Goldman.   

Abstract

The pace of innovation in psychotropic drugs has been rapid over the past 15 years. There also have been unprecedented increases in spending on prescription drugs generally and psychotropic medications specifically. Psychotropic medications are playing a more central role in treatment. They also are receiving close scrutiny from health insurers, state budget makers, and ordinary citizens. Public policy actions regarding prescription drugs have the potential to significantly affect clinical care for mental disorders, the costs of this care to individuals and society at large, and the prospects for future scientific advances. This article outlines the policy issues related to psychotropic drugs with respect to their role in determining access to mental health treatment and the cost and quality of mental health care.

Entities:  

Keywords:  Health Care and Public Health; Mental Health Therapies

Mesh:

Substances:

Year:  2005        PMID: 15960772      PMCID: PMC2690138          DOI: 10.1111/j.1468-0009.2005.00347.x

Source DB:  PubMed          Journal:  Milbank Q        ISSN: 0887-378X            Impact factor:   4.911


  32 in total

1.  Direct-to-consumer advertising--strengthening our health care system.

Authors:  Alan F Holmer
Journal:  N Engl J Med       Date:  2002-02-14       Impact factor: 91.245

2.  Promotion of prescription drugs to consumers.

Authors:  Meredith B Rosenthal; Ernst R Berndt; Julie M Donohue; Richard G Frank; Arnold M Epstein
Journal:  N Engl J Med       Date:  2002-02-14       Impact factor: 91.245

3.  Impact of disseminating quality improvement programs for depression in managed primary care: a randomized controlled trial.

Authors:  K B Wells; C Sherbourne; M Schoenbaum; N Duan; L Meredith; J Unützer; J Miranda; M F Carney; L V Rubenstein
Journal:  JAMA       Date:  2000-01-12       Impact factor: 56.272

4.  Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis.

Authors:  I M Anderson; B M Tomenson
Journal:  BMJ       Date:  1995-06-03

5.  Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates.

Authors:  S A Montgomery; J Henry; G McDonald; T Dinan; M Lader; I Hindmarch; A Clare; D Nutt
Journal:  Int Clin Psychopharmacol       Date:  1994       Impact factor: 1.659

6.  Novel antipsychotics: comparison of weight gain liabilities.

Authors:  D A Wirshing; W C Wirshing; L Kysar; M A Berisford; D Goldstein; J Pashdag; J Mintz; S R Marder
Journal:  J Clin Psychiatry       Date:  1999-06       Impact factor: 4.384

7.  Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.

Authors:  F Song; N Freemantle; T A Sheldon; A House; P Watson; A Long; J Mason
Journal:  BMJ       Date:  1993-03-13

8.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

9.  Patterns of antidepressant use in community practice.

Authors:  G E Simon; M VonKorff; E H Wagner; W Barlow
Journal:  Gen Hosp Psychiatry       Date:  1993-11       Impact factor: 3.238

10.  Predictability of prescription drug expenditures for Medicare beneficiaries.

Authors:  Marian V Wrobel; Jalpa Doshi; Bruce C Stuart; Becky Briesacher
Journal:  Health Care Financ Rev       Date:  2003
View more
  21 in total

1.  Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.

Authors:  Yoonyoung Park; Sonia Hernandez-Diaz; Brian T Bateman; Jacqueline M Cohen; Rishi J Desai; Elisabetta Patorno; Robert J Glynn; Lee S Cohen; Helen Mogun; Krista F Huybrechts
Journal:  Am J Psychiatry       Date:  2018-05-07       Impact factor: 18.112

2.  Economic grand rounds: potential effects of the new medicare drug benefit on pricing for psychotropic medications.

Authors:  Haiden A Huskamp; Judith A Shinogle
Journal:  Psychiatr Serv       Date:  2005-09       Impact factor: 3.084

3.  Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value.

Authors:  Haiden A Huskamp
Journal:  Health Aff (Millwood)       Date:  2006 May-Jun       Impact factor: 6.301

4.  Predicting time-to-independent-release from current level of functioning for psychiatric inpatients: a "survivor" analysis.

Authors:  Justin R Springer; Gordon L Paul
Journal:  J Behav Health Serv Res       Date:  2007-11-21       Impact factor: 1.505

5.  Changes in how health plans provide behavioral health services.

Authors:  Constance M Horgan; Deborah W Garnick; Elizabeth Levy Merrick; Dominic Hodgkin
Journal:  J Behav Health Serv Res       Date:  2007-09-14       Impact factor: 1.505

6.  Availability of addiction medications in private health plans.

Authors:  Constance M Horgan; Sharon Reif; Dominic Hodgkin; Deborah W Garnick; Elizabeth L Merrick
Journal:  J Subst Abuse Treat       Date:  2007-05-17

7.  Antipsychotic Medication Use Among Publicly Insured Pregnant Women in the United States.

Authors:  Yoonyoung Park; Krista F Huybrechts; Jacqueline M Cohen; Brian T Bateman; Rishi J Desai; Elisabetta Patorno; Helen Mogun; Lee S Cohen; Sonia Hernandez-Diaz
Journal:  Psychiatr Serv       Date:  2017-06-15       Impact factor: 3.084

8.  Unmet mental health and substance use treatment needs among older homeless adults: Results from the HOPE HOME Study.

Authors:  Lauren M Kaplan; Lea Vella; Elise Cabral; Lina Tieu; Claudia Ponath; David Guzman; Margot B Kushel
Journal:  J Community Psychol       Date:  2019-08-19

9.  Who are the new users of antipsychotic medications?

Authors:  Marisa Elena Domino; Marvin S Swartz
Journal:  Psychiatr Serv       Date:  2008-05       Impact factor: 3.084

10.  Factors Associated with Geographic Variation in Psychiatric Prescription Drug Expenditures Among Medicaid Beneficiaries.

Authors:  Julia Zur; Leighton Ku
Journal:  J Behav Health Serv Res       Date:  2016-07       Impact factor: 1.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.